Systemic chemotherapy in colorectal cancer
Colon Polyps and Colorectal Cancer: Second Edition, Page: 693-705
2020
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Colorectal cancer is the third most common type of cancer in the world. Relapse and death due to relapse develop in approximately half of the patients after curative resection in colon cancer. Adjuvant therapy is recommended to reduce relapses. Adjuvant treatment has yielded significant survival advantage in colon cancer. On the other hand, surgical resection rates were increased with neoadjuvant chemoradiotherapy in rectal cancer. The combination of 5-fluorouracil + oxaliplatin has become the standard treatment for stage III patients with colon cancer. In stage II patients, adjuvant therapy is recommended only for patients with a high risk of relapse (e.g., lymphovascular invasion, etc.), and 5-fluorouracil-based therapy is the standard treatment. Also, FOLFOX and FOLFIRI have standard primary chemotherapy options for metastatic colorectal cancer treatment. Addition of biological agents to FOLFOX or FOLFIRI chemotherapy increased survival over 2 years. In this section, all systemic therapies in colorectal cancer are examined.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85149291554&origin=inward; http://dx.doi.org/10.1007/978-3-030-57273-0_34; http://link.springer.com/10.1007/978-3-030-57273-0_34; http://link.springer.com/content/pdf/10.1007/978-3-030-57273-0_34; https://dx.doi.org/10.1007/978-3-030-57273-0_34; https://link.springer.com/chapter/10.1007/978-3-030-57273-0_34
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know